BiotechTube

AZD9829 + AZD9829

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematological Malignancies

Conditions

Hematological Malignancies

Trial Timeline

Jan 31, 2024 → Mar 23, 2026

NCT ID
NCT06179511

About AZD9829 + AZD9829

AZD9829 + AZD9829 is a phase 1/2 stage product being developed by AstraZeneca for Hematological Malignancies. The current trial status is active. This product is registered under clinical trial identifier NCT06179511. Target conditions include Hematological Malignancies.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06179511Phase 1/2Active

Competing Products

20 competing products in Hematological Malignancies

See all competitors
ProductCompanyStageHype Score
DS3790a + Combination drug + Combination drugDaiichi SankyoPhase 1/2
41
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
NemtabrutinibMerckPhase 1
33
Study Part 1: KRP203 + Study Part 2: KRP203 lower dose + Study Part 2: KRP203 higher doseNovartisPhase 1
33
LBH589NovartisPhase 1
33
HDM201 + ancillary treatmentNovartisPhase 1
33
Ibandronate + Vitamin SupplementsRochePhase 3
77
Darbepoetin alpha (Aranesp) + Iron saccharate (Venofer)AmgenPhase 2/3
64
Axicabtagene Ciloleucel + Brexucabtagene Autoleucel + Anitocabtagene autleucel + KITE-753 + KITE-197 + KITE-363Gilead SciencesPre-clinical
22
Magrolimab + AzacitidineGilead SciencesPhase 1
32
piperacillin-tazobactam + glycopeptidePfizerPre-clinical
22
Isatuximab SAR650984 + Dexamethasone + DexamethasoneSanofiPhase 1/2
40
Thymoglobulin Injectable ProductSanofiPhase 2
51
ATG + Post-transplantation cyclophosphamideSanofiPre-clinical
22
Mycophenolate Mofetil (MMF) + Thymoglobulin + SirolimusSanofiPhase 2
51
Rituximab + 375 mg/m2 RRituximabBiogenPhase 1/2
38
HMPL-506HUTCHMEDPhase 1
28

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85